Department of Pharmaceutical Chemistry, Semmelweis University, 1092 Budapest, Hőgyes Endre utca. 9, Hungary.
Department of Medical Biochemistry, MTA-SE Laboratory for Neurobiochemistry, Semmelweis University, 1094 Budapest, Tűzoltó utca 37-47, Hungary.
J Pharm Biomed Anal. 2018 Feb 20;150:355-361. doi: 10.1016/j.jpba.2017.12.004. Epub 2017 Dec 16.
Sunitinib is a non-selective tyrosine kinase inhibitor, but in its chemical structure there can be discovered certain features, which suggest the ability to bind to DNA. These elements are the planar aromatic system and the tertiary amine function, which is protonated at the pH of the organism. In this study, the binding of the drug sunitinib to DNA was investigated using circular dichroism (CD), H NMR and UV spectroscopies, along with CD melting. For these studies DNA was isolated from calf thymus (CT), salmon fish sperm (SS), and chicken erythrocyte (CE), however for our purposes an artificially constructed and highly purified plasmid DNA (pUC18) preparation proved to be the most suitable. DNA binding of the drug was confirmed by shifts in the characteristic CD bands of the DNA, the appearance of an induced CD (ICD) signal in the upper absorption region of sunitinib (300 nm-500 nm), and the evidence from CD melting studies and the NMR. Based on the CD and NMR measurements, it can be assumed that sunitinib has a multiple-step binding mechanism.
舒尼替尼是一种非选择性的酪氨酸激酶抑制剂,但在其化学结构中可以发现某些特征,表明其具有与 DNA 结合的能力。这些元素是平面芳香系统和三级胺功能,在生物体的 pH 值下质子化。在这项研究中,使用圆二色性(CD)、H NMR 和 UV 光谱学以及 CD 熔融法研究了药物舒尼替尼与 DNA 的结合。为此,从牛胸腺(CT)、三文鱼精子(SS)和鸡红细胞(CE)中分离出 DNA,但出于我们的目的,人工构建和高度纯化的质粒 DNA(pUC18)制剂被证明是最合适的。通过 DNA 的特征 CD 带的位移、舒尼替尼(300nm-500nm)上吸收区的诱导 CD(ICD)信号的出现以及 CD 熔融研究和 NMR 的证据,证实了药物与 DNA 的结合。基于 CD 和 NMR 测量,可以假设舒尼替尼具有多步结合机制。